|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
1897 participants enrolled in the Multi-Ethnic Study of Atherosclerosis underwent computed tomography to quantify body composition and measurements of adiponectin, leptin, interleukin-6 (IL-6), C-reactive protein (CRP), and resistin.
|
30213651 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin is an adipose tissue-specific protein that is abundantly present in the circulation and suggested to be involved in insulin sensitivity and development of atherosclerosis.
|
12736161 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin, an adipocyte-derived protein, is an essential modulator of insulin sensitivity and several studies suggest an important role of adiponectin in the processes leading to atherosclerosis, thus indicating the adiponectin gene as a potential candidate for coronary artery disease (CAD).
|
15877215 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin, an adipose tissue-derived hormone, exhibits anti-inflammatory properties and has various biological functions, such as increasing insulin sensitivity, reducing hypertension, and suppressing atherosclerosis, liver fibrosis, and tumor growth.
|
16952554 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
Adiponectin (APN) secreted from adipocytes is also one of the important molecules to inhibit the development of atherosclerosis.
|
17521614 |
2007 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin (APN) secreted from adipocytes is one of the important molecules to inhibit the development of atherosclerosis.
|
18703020 |
2008 |
|
Atherosclerosis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Adiponectin is an adipocyte-derived protein that acts to reduce insulin resistance in the liver and muscle and also inhibits atherosclerosis.
|
18931039 |
2009 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin has a variety of metabolic effects on obesity, insulin sensitivity, and atherosclerosis.
|
19165155 |
2009 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin is inversely associated with obesity, insulin resistance, and atherosclerosis, but little is known about the genetic pathways that regulate the plasma level of this protein.
|
19426517 |
2009 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin is an insulin-sensitizing and anti-inflammatory fat cell hormone that has immense potential as a therapeutic target for a multitude of obesity-associated diseases, including type 2 diabetes, NASH and atherosclerosis (Chandran M, Phillips SA, Ciaraldi T, Henry RR: Adiponectin: more than just another fat cell hormone?Diabetes Care 2003, 26:2442-2450).
|
20810317 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin is an adipose tissue-specific hormone which is inversely associated with metabolic alterations related to atherosclerosis.
|
21938426 |
2012 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin is a hormone that is derived from adipose tissue and is reduced in obesity-linked diseases including insulin resistance/type 2 diabetes and atherosclerosis.
|
24417942 |
2014 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin exerts anti-atherosclerosis property through its 2 receptors (AdipoR1 and AdipoR2).
|
25865302 |
2015 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin is a protein secreted by white adipocytes that plays an important role in insulin action, energy homeostasis and the development of atherosclerosis.
|
28606474 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin regulates glucose and lipid metabolism, acting against atherosclerosis and metabolic syndrome.
|
28606559 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin, an adipocyte-derived protein, is known to play a key role in the processes leading to atherosclerosis and coronary artery disease (CAD) through its anti-atherogenic, anti-inflammatory, antioxidative, and anti-apoptotic properties.
|
29633340 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin plays a critically biological role in atherosclerosis, glucose utilization, lipid and carbohydrate metabolism, and triglyceride synthesis in animals and humans.
|
30511299 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin is a major anti-inflammatory mediator and so we hypothesized an effect of TRPC5 on the inflammatory condition of atherosclerosis.
|
30692584 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin (APN), an adipocyte-derived protein that is abundant in circulation, reportedly protects against atherosclerosis.
|
31030940 |
2019 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A decrease in the circulating levels of adiponectin by interactions between genetic factors and environmental factors causing obesity has been shown to contribute to the development of insulin resistance, type 2 diabetes, metabolic syndrome and atherosclerosis.
|
18054335 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
A lack of increase in high molecular weight-adiponectin in macroalbuminuric subjects with metabolic syndrome may exert renal and atherosclerotic risks.
|
18006102 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A large number of in vitro and in vivo studies support the beneficial effects of adiponectin on metabolic syndrome, diabetes, and atherosclerosis.
|
20232346 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin.
|
12890697 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A subset of the original Multi-Ethnic Study of Atherosclerosis cohort (n = 1,968) had adiponectin, leptin, and resistin measured during follow-up visits (2002-2005).
|
31678306 |
2020 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 1,944 participants who enrolled in the Multi-Ethnic Study of Atherosclerosis underwent computed tomography to quantify body composition and measurements of adiponectin, leptin, interleukin-6, C-reactive protein, and resistin.
|
29877610 |
2018 |